<DOC>
	<DOC>NCT01403025</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).</brief_summary>
	<brief_title>Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects with type 2 diabetes mellitus, including newlydiagnosed subjects, who require treatment with liraglutide Subjects who are or have previously been on liraglutide Subjects who have previously been enrolled in the study Subjects with a hypersensitivity to liraglutide or to any of the excipients Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods Subjects with cancer (except basal cell skin cancer or squamous cell skin cancer) or any clinically significant disorder, except for conditions associated with type 2 diabetes mellitus history which in the physicians' opinion could interfere with the results of the trial Known or suspected abuse of alcohol or narcotics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>